We live for the thrill of discovery. Our scientists collaborate closely with you to ensure seamless communication and delivery from target to lead candidate. We assign a dedicated project leader to ensure that you receive the focus and attention your drug discovery needs.
We understand our clients’ challenges, especially those of emerging pharma companies, and work hard to deliver appropriate solutions. We delight at the moment of discovery and share the joy of success with you when we find out you have subsequently had clinical success. We are flexible, adaptable and innovative both in our science and in how we contract with you.
How we do it
As a team with wide-ranging and detailed experience gained within pharmaceutical, biotech and fine chemicals companies, we can provide expertise at all stages of the drug discovery pipeline, and provide synthetic and scale-up support to other sectors such as agrochemicals and materials chemistry.
Whether you need our services of target identification, hit identification and evaluation, hit to lead, lead optimisation, or method development, scale-up and process research chemistry, we offer an end-to-end solution.
Changing lives for the better
One example from our portfolio of success stories, demonstrating what can be achieved when innovation, research excellence and collaboration form the basis of CRO-Client relationships is our work with NFlection Therapeutics. It led to the first clinical trial of NFlection’s lead product, NFX-179 Gel, a topically applied therapy for the mitigation of Cutaneous Neurofibromatosis Type-1.
NFlection is working to develop first-in-class soft MEK (mitogen-activated protein kinase) inhibitors as topical treatments to mitigate or treat cutaneous neurofibromas in neurofibromatosis type 1, congenital birthmarks and immunosuppressant-mediated squamous cell carcinoma – a currently unmet clinical need.
During a highly successful research collaboration, Charnwood Molecular’s medicinal chemistry group supported NFlection in the identification of NFX-179. Our chemical development team then provided rapid delivery of the first scale-up batches of API for non-clinical studies and the confirmation of a robust and efficient synthetic route to support clinical manufacture. Working closely with the Nflection team, this led to a seamless technology transfer to a cGMP facility where multi-kilo batches were prepared.
This collaboration demonstrates what can be achieved when innovation, research excellence and collaboration form the basis of CRO-client relationships, and highlights the advantage of the combined medicinal chemistry and process research capability at Charnwood Molecular.
Meet the team
We know that a company’s real strengths lie in the people that it employs. At Charnwood Molecular, our teams bring a wealth of creative experience and proven track records as research scientists within academia, CRO’s, fine chemicals, biotech and from major global pharmaceutical companies.meet the team